FENNEC PHARMACEUTICALS INC. Proceeds from Long-Term Debt Issued
FENNEC PHARMACEUTICALS INC. (FENC) reported Proceeds from Long-Term Debt Issued of $5.00 million for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-26.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfLongTermDebt · last filed 2025-03-26
- FENNEC PHARMACEUTICALS INC. proceeds from issuance of long-term debt for the quarter ending 2022-12-31 was -$65.00K.
- FENNEC PHARMACEUTICALS INC. proceeds from issuance of long-term debt for the quarter ending 2021-12-31 was $0.00.
- FENNEC PHARMACEUTICALS INC. proceeds from issuance of long-term debt for the quarter ending 2021-09-30 was $0.00.
- FENNEC PHARMACEUTICALS INC. proceeds from issuance of long-term debt for the quarter ending 2021-06-30 was $5.00M.
- FENNEC PHARMACEUTICALS INC. proceeds from issuance of long-term debt for fiscal 2023 was $5.00M, a 79.96% decline from fiscal 2022.
- FENNEC PHARMACEUTICALS INC. proceeds from issuance of long-term debt for fiscal 2022 was $24.93M, a 398.70% increase from fiscal 2021.
- FENNEC PHARMACEUTICALS INC. proceeds from issuance of long-term debt for fiscal 2021 was $5.00M.
| Period end | Proceeds from Issuance of Long-term Debt 3 month | Proceeds from Issuance of Long-term Debt 6 month | Proceeds from Issuance of Long-term Debt 9 month | Proceeds from Issuance of Long-term Debt 12 month |
|---|---|---|---|---|
| 2023-12-31 | $5.00M 10-K · filed 2025-03-26 | |||
| 2022-12-31 | -$65.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $24.93M 10-K · filed 2024-03-29 | ||
| 2022-09-30 | $25.00M 10-Q · filed 2023-11-09 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $0.00 derived: sum of 2 quarters · filed 2023-03-29 | $5.00M derived: sum of 3 quarters · filed 2023-03-29 | $5.00M 10-K · filed 2023-03-29 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $5.00M derived: sum of 2 quarters · filed 2022-11-14 | $5.00M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $5.00M 10-Q · filed 2021-08-10 | $5.00M 10-Q · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |